Transthyretin Kinetic Stabilizers for ATTR Amyloidosis.
作者信息
Kelly Jeffery W
机构信息
Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.
出版信息
Cardiol Ther. 2025 Sep;14(3):327-331. doi: 10.1007/s40119-025-00422-8. Epub 2025 Jul 29.
Abstract
摘要
相似文献
1
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis.
Cardiol Ther. 2025 Sep;14(3):327-331. doi: 10.1007/s40119-025-00422-8. Epub 2025 Jul 29.
2
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits.
Cardiol Ther. 2025 Sep;14(3):333-350. doi: 10.1007/s40119-025-00423-7. Epub 2025 Jul 29.
3
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
JACC CardioOncol. 2022 Nov 15;4(4):442-454. doi: 10.1016/j.jaccao.2022.07.007. eCollection 2022 Nov.
4
Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Drugs Today (Barc). 2019 Dec;55(12):727-734. doi: 10.1358/dot.2019.55.12.3078389.
5
Transthyretin: Its function and amyloid formation.
Neurochem Int. 2022 May;155:105313. doi: 10.1016/j.neuint.2022.105313. Epub 2022 Feb 23.
6
Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Curr Heart Fail Rep. 2022 Oct;19(5):356-363. doi: 10.1007/s11897-022-00570-1. Epub 2022 Aug 5.
7
Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Ann Pharmacother. 2021 Dec;55(12):1502-1514. doi: 10.1177/10600280211000351. Epub 2021 Mar 9.
8
Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery.
Biomedicines. 2025 Jul 6;13(7):1647. doi: 10.3390/biomedicines13071647.
9
Biomarkers in Subclinical Transthyretin Cardiac Amyloidosis.
Curr Heart Fail Rep. 2025 Feb 13;22(1):8. doi: 10.1007/s11897-025-00696-y.
10
Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population: A Pilot Study.
JACC CardioOncol. 2021 Oct 19;3(4):565-576. doi: 10.1016/j.jaccao.2021.08.008. eCollection 2021 Oct.
本文引用的文献
1
Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction.
Eur J Heart Fail. 2024 Sep;26(9):2038-2046. doi: 10.1002/ejhf.3330. Epub 2024 Jun 26.
2
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS).
J Card Fail. 2025 Mar;31(3):525-533. doi: 10.1016/j.cardfail.2024.06.003. Epub 2024 Jun 21.
3
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Eur J Heart Fail. 2024 Mar;26(3):612-615. doi: 10.1002/ejhf.3190. Epub 2024 Mar 4.
4
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
5
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
JACC Heart Fail. 2024 Jan;12(1):150-160. doi: 10.1016/j.jchf.2023.08.032. Epub 2023 Nov 8.
6
Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Eur J Heart Fail. 2023 Nov;25(11):2060-2064. doi: 10.1002/ejhf.2974. Epub 2023 Jul 26.
7
Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response.
Amyloid. 2023 Mar;30(1):81-95. doi: 10.1080/13506129.2022.2126308. Epub 2022 Sep 30.
8
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.
9
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):529-538. doi: 10.1093/ehjqcco/qcab031.
10
Response.
Amyloid. 2021 Jun;28(2):140-141. doi: 10.1080/13506129.2020.1853094. Epub 2020 Dec 4.
Zotero 插件